HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Joon Koo Han Selected Research

N- (4- (3- (1H- 1,2,4- triazol- 1- yl)- 4- (3,4,5- trimethoxybenzoyl)phenyl)thiazol- 2- yl)- 2- amino- 3- methylbutanamide

1/2016Monitoring Vascular Disrupting Therapy in a Rabbit Liver Tumor Model: Relationship between Tumor Perfusion Parameters at IVIM Diffusion-weighted MR Imaging and Those at Dynamic Contrast-enhanced MR Imaging.
8/2014Intravoxel incoherent motion diffusion-weighted MR imaging for monitoring the therapeutic efficacy of the vascular disrupting agent CKD-516 in rabbit VX2 liver tumors.
1/2014Early quantification of the therapeutic efficacy of the vascular disrupting agent, CKD-516, using dynamic contrast-enhanced ultrasonography in rabbit VX2 liver tumors.
10/2013Vascular disrupting effect of CKD-516: preclinical study using DCE-MRI.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Joon Koo Han Research Topics

Disease

58Hepatocellular Carcinoma (Hepatoma)
07/2022 - 01/2002
55Neoplasms (Cancer)
04/2022 - 01/2002
14Necrosis
03/2017 - 01/2004
11Liver Diseases (Liver Disease)
12/2021 - 04/2005
10Neoplasm Metastasis (Metastasis)
01/2017 - 07/2004
10Pathologic Constriction (Stenosis)
11/2016 - 04/2002
8Pancreatic Neoplasms (Pancreatic Cancer)
10/2021 - 09/2009
8Fibrosis (Cirrhosis)
01/2020 - 03/2008
8Rectal Neoplasms (Rectal Cancer)
01/2020 - 07/2008
8Stomach Neoplasms (Stomach Cancer)
01/2019 - 03/2002
7Carcinoma (Carcinomatosis)
01/2019 - 09/2003
5Colorectal Neoplasms (Colorectal Cancer)
11/2018 - 12/2011
4Adenocarcinoma
10/2021 - 09/2017
4Polyps
07/2019 - 07/2007
4Thrombosis (Thrombus)
01/2019 - 09/2004
4Liver Cirrhosis (Hepatic Cirrhosis)
10/2017 - 01/2008
4Bile Duct Neoplasms (Bile Duct Cancer)
07/2013 - 05/2007
3Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor)
03/2020 - 07/2004
3Cholangiocarcinoma
11/2016 - 09/2012
3Esophageal and Gastric Varices (Esophageal Varices)
06/2016 - 07/2008
3Jaundice (Icterus)
12/2003 - 05/2002
2Ascites
04/2021 - 01/2018
2Residual Neoplasm
07/2019 - 02/2011
2Cholangitis
04/2019 - 10/2017
2Primitive Neuroectodermal Tumors (PNET)
04/2018 - 01/2017
2Hypoxia (Hypoxemia)
01/2018 - 10/2017
2Adenoma (Adenomas)
09/2017 - 01/2010
2Infections
04/2017 - 07/2003
2Varicose Veins (Varicose Vein)
06/2016 - 07/2008
2Colonic Neoplasms (Colon Cancer)
05/2016 - 11/2012
2Obstructive Jaundice (Cholestatic Jaundice)
12/2012 - 05/2002
2Lymphatic Metastasis
05/2012 - 04/2010
2Hemorrhage
12/2010 - 10/2005
2Klatskin Tumor
02/2008 - 05/2007
2Abscess
05/2006 - 02/2004
2Fistula
05/2006 - 12/2003
1Pain (Aches)
04/2021
1Non-alcoholic Fatty Liver Disease
01/2021
1Portal Hypertension
01/2020
1Crohn Disease (Crohn's Disease)
11/2018
1Neuroendocrine Tumors (Neuroendocrine Tumor)
04/2018

Drug/Important Bio-Agent (IBA)

28gadolinium ethoxybenzyl DTPAFDA Link
06/2021 - 01/2010
11Contrast MediaIBA
10/2020 - 01/2002
8GadoliniumIBA
01/2016 - 05/2007
7ferric oxide (iron oxide)IBA
04/2019 - 02/2006
6Therapeutic UsesIBA
04/2021 - 05/2002
4Capsules (Microcapsules)IBA
01/2019 - 12/2010
4N- (4- (3- (1H- 1,2,4- triazol- 1- yl)- 4- (3,4,5- trimethoxybenzoyl)phenyl)thiazol- 2- yl)- 2- amino- 3- methylbutanamideIBA
01/2016 - 10/2013
4allogenic effect factor (AEF)IBA
01/2013 - 02/2009
3perfluorobutane (AI 700)IBA
07/2022 - 10/2020
3Doxorubicin (Adriamycin)FDA LinkGeneric
01/2022 - 01/2020
3Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link
03/2020 - 11/2012
3Sorafenib (BAY 43-9006)FDA Link
01/2020 - 12/2015
3IodineIBA
11/2018 - 02/2011
3CholesterolIBA
09/2017 - 12/2010
3gadobutrolIBA
01/2017 - 04/2010
3GemcitabineFDA Link
09/2016 - 11/2013
3Pharmaceutical PreparationsIBA
09/2015 - 11/2013
3SolutionsIBA
11/2013 - 01/2004
3BilirubinIBA
01/2013 - 08/2002
2folfirinoxIBA
10/2021 - 06/2021
2Sulfur HexafluorideIBA
10/2020 - 10/2020
2AlbuminsIBA
01/2020 - 02/2017
2Biological ProductsIBA
04/2018 - 01/2002
2Proteins (Proteins, Gene)FDA Link
01/2018 - 10/2017
2Dimethylnitrosamine (Nitrosodimethylamine)IBA
10/2017 - 04/2017
2Biomarkers (Surrogate Marker)IBA
02/2017 - 06/2013
2LuciferasesIBA
09/2016 - 09/2006
2alpha-Fetoproteins (alpha-Fetoprotein)IBA
06/2014 - 10/2004
2Gadolinium DTPA (Magnevist)FDA Link
01/2013 - 09/2003
2perfluoro- 2,2,2',2'- tetramethyl- 4,4'- bis(1,3- dioxolane)IBA
12/2012 - 05/2002
2Polytetrafluoroethylene (Teflon)FDA Link
11/2012 - 09/2011
2gadobenic acid (gadobenate dimeglumine)FDA Link
08/2008 - 03/2008
2SHU 508 (Levovist)IBA
04/2005 - 01/2002
11,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acidIBA
10/2021
1Opioid Analgesics (Opioids)IBA
04/2021
1EnzymesIBA
01/2021
1Vitamin KFDA Link
01/2020
14-(3-chlorophenylsulfanyl)piperidineIBA
01/2020
1acarboxyprothrombin (PIVKA)IBA
01/2020
1ErbB Receptors (EGF Receptor)IBA
01/2019
1Protons (Proton)IBA
01/2019
1F 4 (F-4)IBA
11/2017
1Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
10/2017

Therapy/Procedure

26Radiofrequency Ablation
04/2021 - 04/2004
17Electrodes (Electrode)
01/2018 - 04/2004
14Liver Transplantation
01/2022 - 03/2007
11Drug Therapy (Chemotherapy)
01/2019 - 07/2009
10Therapeutics
04/2022 - 05/2006
8Stents
11/2016 - 01/2002
7Neoadjuvant Therapy
07/2019 - 05/2009
6Aftercare (After-Treatment)
01/2020 - 07/2003
4Microbubbles
01/2022 - 09/2016
4Catheters
09/2013 - 02/2004
3Cholecystectomy
07/2019 - 08/2004
3Palliative Care (Palliative Therapy)
01/2013 - 08/2002
2Hepatectomy
06/2019 - 01/2017
2Gastrectomy
01/2015 - 03/2002
2Self Expandable Metallic Stents
01/2013 - 02/2004
1Chemoradiotherapy
01/2020